BENESOVA, Lucie, Tereza HALKOVA, Renata PTACKOVA, Anastasiya SEMYAKINA, Katerina MENCLOVA, Jiri PUDIL, Miroslav RYSKA, Miroslav LEVY, Jaromir SIMSA, Filip PAZDIREK, Jiri HOCH, Milan BLAHA a Marek MINARIK. Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA. World Journal of Gastroenterology. Baishideng, 2019, roč. 25, č. 48, s. 6939-6948. ISSN 1007-9327. Dostupné z: https://dx.doi.org/10.3748/wjg.v25.i48.6939.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA
Autoři BENESOVA, Lucie (203 Česká republika, garant), Tereza HALKOVA (203 Česká republika), Renata PTACKOVA (203 Česká republika), Anastasiya SEMYAKINA (203 Česká republika), Katerina MENCLOVA (203 Česká republika), Jiri PUDIL (203 Česká republika), Miroslav RYSKA (203 Česká republika), Miroslav LEVY (203 Česká republika), Jaromir SIMSA (203 Česká republika), Filip PAZDIREK (203 Česká republika), Jiri HOCH (203 Česká republika), Milan BLAHA (203 Česká republika, domácí) a Marek MINARIK (203 Česká republika).
Vydání World Journal of Gastroenterology, Baishideng, 2019, 1007-9327.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30219 Gastroenterology and hepatology
Stát vydavatele Spojené státy
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 3.665
Kód RIV RIV/00216224:14110/19:00108601
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.3748/wjg.v25.i48.6939
UT WoS 000511328600007
Klíčová slova anglicky Circulating tumor DNA; Metastatic colorectal cancer; Postoperative; Radicality of resection; Follow-up; Recurrence
Štítky 14119612, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 19. 2. 2020 10:37.
Anotace
BACKGROUND One of the most notable applications for circulating tumor DNA (ctDNA) detection in peripheral blood of patients with metastatic colorectal cancer (mCRC) is a long-term postoperative follow-up. Sometimes referred to as a "liquid (re)biopsy" it is a minimally invasive procedure and can be performed repeatedly at relatively short intervals (months or even weeks). The presence of the disease and the actual extent of the tumor burden (tumor mass) within the patient's body can be monitored. This is of particular importance, especially when evaluating radicality of surgical treatment as well as for early detection of disease progression or recurrence. AIM To confirm the radicality of surgery using ctDNA and compare available methods for detection of recurrence in metastatic colorectal cancer. METHODS A total of 47 patients with detected ctDNA and indications for resection of mCRC were enrolled in the multicenter study involving three surgical centers. Standard postoperative follow-ups using imaging techniques and the determination of tumor markers were supplemented by ctDNA sampling. In addition to the baseline ctDNA testing prior to surgery, a postoperative observation was conducted by evaluating ctDNA presence up to a week after surgery and subsequently at approximately three-month intervals. The presence of ctDNA was correlated with radicality of surgical treatment and the actual clinical status of the patient. RESULTS Among the monitored patients, the R0 (curative) resection correlated with postoperative ctDNA negativity in 26 out of 28 cases of surgical procedures (26/28, 93%). In the remaining cases of R0 surgeries that displayed ctDNA, both patients were diagnosed with a recurrence of the disease after 6 months. In 7 patients who underwent an R1 resection, 4 ctDNA positivities (4/7, 57%) were detected after surgery and associated with the confirmation of early disease recurrence (after 3 to 7 months). All 15 patients (15/15, 100%) undergoing R2 resection remained constantly ctDNA positive during the entire follow-up period. In 22 cases of recurrence, ctDNA positivity was detected 22 times (22/22, 100%) compared to 16 positives (16/22, 73%) by imaging methods and 15 cases (15/22, 68%) of elevated tumor markers. CONCLUSION ctDNA detection in patients with mCRC is a viable tool for early detection of disease recurrence as well as for confirmation of the radicality of surgical treatment.
Návaznosti
NV15-27939A, projekt VaVNázev: Přínos nové technologie „liquid biopsy“ pro monitoraci komplexní léčby kolorektálního karcinomu ve 3.- 4. stádiu onemocnění
VytisknoutZobrazeno: 12. 5. 2024 16:53